Cargando…

Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2

BACKGROUND: Vasohibin 2 (VASH2) has previously been identified as an agiogenenic factor and a cancer related protein. Here we investigated the association of VASH2 expression and chemoresistance in pancreatic cancer. METHODS: Immunohistochemical staining for VASH2 was performed on 102 human pancreat...

Descripción completa

Detalles Bibliográficos
Autores principales: Tu, Min, Li, Haifeng, Lv, Nan, Xi, Chunhua, Lu, Zipeng, Wei, Jishu, Chen, Jianmin, Guo, Feng, Jiang, Kuirong, Song, Guoxin, Gao, Wentao, Miao, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5360034/
https://www.ncbi.nlm.nih.gov/pubmed/28327155
http://dx.doi.org/10.1186/s12943-017-0619-6
_version_ 1782516515100164096
author Tu, Min
Li, Haifeng
Lv, Nan
Xi, Chunhua
Lu, Zipeng
Wei, Jishu
Chen, Jianmin
Guo, Feng
Jiang, Kuirong
Song, Guoxin
Gao, Wentao
Miao, Yi
author_facet Tu, Min
Li, Haifeng
Lv, Nan
Xi, Chunhua
Lu, Zipeng
Wei, Jishu
Chen, Jianmin
Guo, Feng
Jiang, Kuirong
Song, Guoxin
Gao, Wentao
Miao, Yi
author_sort Tu, Min
collection PubMed
description BACKGROUND: Vasohibin 2 (VASH2) has previously been identified as an agiogenenic factor and a cancer related protein. Here we investigated the association of VASH2 expression and chemoresistance in pancreatic cancer. METHODS: Immunohistochemical staining for VASH2 was performed on 102 human pancreatic cancer samples. Pancreatic cancer cell line models exhibiting overexpression or knockdown of VASH2 were generated. Gene expression analyses were carried out to determine genes differentially regulated by VASH2. Putative transcription factors that are downstream mediators of gene expression regulated by VASH2 were queried bioinformatically. Dual-luciferase reporter assays and ChIP assays were performed to confirm transactivation of target genes following VASH2 overexpression or knockdown. RESULTS: VASH2 protein expression was higher in human pancreatic cancer than in paired adjacent tissues and elevated VASH2 levels were associated with gemcitabine chemoresistance. In cell line models of pancreatic cancer, VASH2 expression induced gemcitabine chemoresistance in vitro and in vivo. It was discovered that expression of ribonucleotide reductase regulatory subunit M2 (RRM2) is regulated by VASH2; immunohistochemical analysis demonstrated a positive association of VASH2 expression and RRM2 expression in human pancreatic cancer tissues. Bioinformatics analyses revealed that induction of the Jun proto-oncogene (JUN) by VASH2 is responsible for upregulation of RRM2 expression; this JUN-dependent regulation of RRM2 by VASH2 was confirmed by chromatin immunoprecipitation and dual luciferase reporter assays, which demonstrated that JUN directly binds with the RRM2 promoter to activate transcription. CONCLUSIONS: These data suggest that VASH2 reduces the chemosensitivity to gemcitabine in pancreatic cancer cells via JUN-dependent transactivation of RRM2. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12943-017-0619-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5360034
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-53600342017-03-24 Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2 Tu, Min Li, Haifeng Lv, Nan Xi, Chunhua Lu, Zipeng Wei, Jishu Chen, Jianmin Guo, Feng Jiang, Kuirong Song, Guoxin Gao, Wentao Miao, Yi Mol Cancer Research BACKGROUND: Vasohibin 2 (VASH2) has previously been identified as an agiogenenic factor and a cancer related protein. Here we investigated the association of VASH2 expression and chemoresistance in pancreatic cancer. METHODS: Immunohistochemical staining for VASH2 was performed on 102 human pancreatic cancer samples. Pancreatic cancer cell line models exhibiting overexpression or knockdown of VASH2 were generated. Gene expression analyses were carried out to determine genes differentially regulated by VASH2. Putative transcription factors that are downstream mediators of gene expression regulated by VASH2 were queried bioinformatically. Dual-luciferase reporter assays and ChIP assays were performed to confirm transactivation of target genes following VASH2 overexpression or knockdown. RESULTS: VASH2 protein expression was higher in human pancreatic cancer than in paired adjacent tissues and elevated VASH2 levels were associated with gemcitabine chemoresistance. In cell line models of pancreatic cancer, VASH2 expression induced gemcitabine chemoresistance in vitro and in vivo. It was discovered that expression of ribonucleotide reductase regulatory subunit M2 (RRM2) is regulated by VASH2; immunohistochemical analysis demonstrated a positive association of VASH2 expression and RRM2 expression in human pancreatic cancer tissues. Bioinformatics analyses revealed that induction of the Jun proto-oncogene (JUN) by VASH2 is responsible for upregulation of RRM2 expression; this JUN-dependent regulation of RRM2 by VASH2 was confirmed by chromatin immunoprecipitation and dual luciferase reporter assays, which demonstrated that JUN directly binds with the RRM2 promoter to activate transcription. CONCLUSIONS: These data suggest that VASH2 reduces the chemosensitivity to gemcitabine in pancreatic cancer cells via JUN-dependent transactivation of RRM2. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12943-017-0619-6) contains supplementary material, which is available to authorized users. BioMed Central 2017-03-21 /pmc/articles/PMC5360034/ /pubmed/28327155 http://dx.doi.org/10.1186/s12943-017-0619-6 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Tu, Min
Li, Haifeng
Lv, Nan
Xi, Chunhua
Lu, Zipeng
Wei, Jishu
Chen, Jianmin
Guo, Feng
Jiang, Kuirong
Song, Guoxin
Gao, Wentao
Miao, Yi
Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2
title Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2
title_full Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2
title_fullStr Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2
title_full_unstemmed Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2
title_short Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2
title_sort vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit m2
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5360034/
https://www.ncbi.nlm.nih.gov/pubmed/28327155
http://dx.doi.org/10.1186/s12943-017-0619-6
work_keys_str_mv AT tumin vasohibin2reduceschemosensitivitytogemcitabineinpancreaticcancercellsviajunprotooncogenedependenttransactivationofribonucleotidereductaseregulatorysubunitm2
AT lihaifeng vasohibin2reduceschemosensitivitytogemcitabineinpancreaticcancercellsviajunprotooncogenedependenttransactivationofribonucleotidereductaseregulatorysubunitm2
AT lvnan vasohibin2reduceschemosensitivitytogemcitabineinpancreaticcancercellsviajunprotooncogenedependenttransactivationofribonucleotidereductaseregulatorysubunitm2
AT xichunhua vasohibin2reduceschemosensitivitytogemcitabineinpancreaticcancercellsviajunprotooncogenedependenttransactivationofribonucleotidereductaseregulatorysubunitm2
AT luzipeng vasohibin2reduceschemosensitivitytogemcitabineinpancreaticcancercellsviajunprotooncogenedependenttransactivationofribonucleotidereductaseregulatorysubunitm2
AT weijishu vasohibin2reduceschemosensitivitytogemcitabineinpancreaticcancercellsviajunprotooncogenedependenttransactivationofribonucleotidereductaseregulatorysubunitm2
AT chenjianmin vasohibin2reduceschemosensitivitytogemcitabineinpancreaticcancercellsviajunprotooncogenedependenttransactivationofribonucleotidereductaseregulatorysubunitm2
AT guofeng vasohibin2reduceschemosensitivitytogemcitabineinpancreaticcancercellsviajunprotooncogenedependenttransactivationofribonucleotidereductaseregulatorysubunitm2
AT jiangkuirong vasohibin2reduceschemosensitivitytogemcitabineinpancreaticcancercellsviajunprotooncogenedependenttransactivationofribonucleotidereductaseregulatorysubunitm2
AT songguoxin vasohibin2reduceschemosensitivitytogemcitabineinpancreaticcancercellsviajunprotooncogenedependenttransactivationofribonucleotidereductaseregulatorysubunitm2
AT gaowentao vasohibin2reduceschemosensitivitytogemcitabineinpancreaticcancercellsviajunprotooncogenedependenttransactivationofribonucleotidereductaseregulatorysubunitm2
AT miaoyi vasohibin2reduceschemosensitivitytogemcitabineinpancreaticcancercellsviajunprotooncogenedependenttransactivationofribonucleotidereductaseregulatorysubunitm2